

# **Original Investigation**

**ONLINE FIRST** 

November 25, 2019

# Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation

Pamela L. Lutsey, PhD<sup>1</sup>; Faye L. Norby, MPH<sup>1</sup>; Kristine E. Ensrud, MD<sup>1,2,3</sup>; et al

### » Author Affiliations

JAMA Intern Med. Published online November 25, 2019. doi:https://doi.org/10.1001/jamainternmed.2019.5679

# **Key Points**

**Question** Are oral anticoagulants differentially associated with risk of fracture among patients with atrial fibrillation?

**Findings** In this comparative effectiveness cohort study of 167 275 patients with atrial fibrillation, direct oral anticoagulants (ie, dabigatran, rivaroxaban, and apixaban) were associated with modestly lower fracture risk compared with warfarin. This protective association was more pronounced among patients with atrial fibrillation who also had a diagnosis of osteoporosis; among the direct oral anticoagulants, fracture risk was lowest among apixaban users.

**Meaning** These findings add to speculation that warfarin may be harmful to bone health and suggest that direct oral anticoagulants may be preferred among patients with atrial fibrillation and high fracture risk.

# Abstract

**Importance** Warfarin is prescribed to patients with atrial fibrillation (AF) for the prevention of cardioembolic complications. Whether warfarin adversely affects bone health is controversial. The availability of alternate direct oral anticoagulant (DOAC) options now make it possible to evaluate the comparative safety of warfarin in association with fracture risk.

**Objective** To test the hypothesis that, among patients with nonvalvular AF, use of DOACs vs warfarin is associated with lower risk of incident fracture.

**Design, Setting, and Participants** This comparative effectiveness cohort study used the MarketScan administrative claims databases to identify patients with nonvalvular AF and who were prescribed oral anticoagulants from January 1, 2010, through September 30, 2015. To reduce confounding, patients were matched on age, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc (congestive heart failure, hypertension, age [>65 years = 1 point; >75 years = 2 points], diabetes, and previous stroke/transient ischemic attack [2 points], vascular disease) score, and high-dimensional propensity scores. The final analysis included 167 275 patients with AF. Data were analyzed from February 27, 2019 to September 18, 2019.

**Exposures** Warfarin and DOACs (dabigatran etexilate, rivaroxaban, and apixaban).

**Main Outcomes and Measures** Incident hip fracture, fracture requiring hospitalization, and all clinical fractures (identified using inpatient or outpatient claims) defined by *International Classification of Diseases, Ninth Revision, Clinical Modification* codes.

**Results** In the study population of 167 275 patients with AF (38.0% women and 62.0% men; mean [SD] age, 68.9 [12.5] years), a total of 817 hip fractures, 2013 hospitalized fractures, and 7294 total fractures occurred during a mean (SD) follow-up of 16.9 (13.7) months. In multivariable-adjusted, propensity score-matched Cox proportional hazards regression models, relative to new users of warfarin, new users of DOACs tended to be at lower risk of fractures requiring hospitalization (hazard ratio [HR], 0.87; 95% CI, 0.79-0.96) and all clinical fractures (HR, 0.93; 95% CI, 0.88-0.98), whereas the association with hip fractures (HR, 0.91; 95% CI, 0.78-1.07) was not statistically significant. When comparing individual DOACs with warfarin, the strongest findings were for apixaban (HR for hip fracture, 0.67 [95% CI, 0.45-0.98]; HR for fractures requiring hospitalization, 0.60 [95% CI, 0.47-0.78]; and HR for all clinical fractures, 0.86 [95% CI, 0.75-0.98]). In subgroup analyses, DOACs appeared more beneficial among patients with AF who also had a diagnosis of osteoporosis than among those without a diagnosis of osteoporosis.

**Conclusions and Relevance** In this real-world population of 167 275 patients with AF, use of DOACs—particularly apixaban—compared with warfarin use was associated with lower fracture risk. These associations were more pronounced among patients with a diagnosis of osteoporosis. Given the potential adverse effects of warfarin on bone health, these findings suggest that caution should be used when prescribing warfarin to patients with AF at high risk of fracture.





#### d)) Browse and subscribe to JAMA Network podcasts!

# Trending

#### Research

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant *November 1, 2019* 

#### Research

Underappreciated Bias Created by Measurement Error in Risk Factor Assessment December 9, 2019

## Opinion 😔

Coagulation Testing in Patients Taking Direct Oral Anticoagulants September 1, 2019 Advertisement

#### JOB LISTINGS ON JAMA CAREER CENTER®

Internist White Plains, New York

Internal Medicine Physician Mexico, MO

Physician - Cardiology Interventional Indiana

> Physician Specialist Piscataway, New Jersey

Physician-Internal Medicine-SSM Health Madison, WI

See more at JAMA Career Center

# **Others Also Liked**

#### DOACs Are Associated With Lower Fracture Risk Among Patients With AF

PracticeUpdate, 2019

# Direct Oral Anticoagulants Associated With Lower Risk of Liver Injury in Patients With Atrial Fibrillation

PracticeUpdate, 2017

#### Warfarin users may have higher risk for fracture

Healio

Powered by **TREND MD** 

# Trending

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

JAMA Internal Medicine | Research | November 1, 2019

## Underappreciated Bias Created by Measurement Error in Risk Factor Assessment

JAMA Internal Medicine | Research |

December 9, 2019

### Effect of Topical Brimonidine on Alcohol-Induced Flushing in Asian Individuals

JAMA Dermatology | Research |

December 4, 2019